Yeah, I've got no idea why this is price sensitive either.
I also see that this is on the old format, the new style is much nicer.
Paul did his talk today, I was unable to attend due to work commitments, but for existing holders, there isn't any new information, and for new holders, I think the style and format leaves a bit to be desired.
Ask of the presentations on the works don't matter, we need the bloody scoping study.
It would also be good to see directors buying on market. Perhaps they can't because they have the first scoping study, but one the second scoping study is released, is like to see some buying.
Add to My Watchlist
What is My Watchlist?
